Navigation Links
Latest RAD001 Study Results Show Further Increase in Time Without Tumor Growth in Patients With Advanced Kidney Cancer
Date:9/15/2008

is an investigational drug being studied in multiple tumor types. In cancer cells, RAD001 provides continuous inhibition of mTOR, a protein that acts as a central regulator of tumor cell division, cell metabolism and blood vessel growth. If approved, RAD001 will become the first oral, once-daily therapy that targets mTOR to treat advanced kidney cancer.

The safety and efficacy profile of RAD001 has not yet been established in oncology and there is no guarantee that RAD001 will become commercially available for oncology indications. The active ingredient in RAD001 is everolimus, which is available in different dosage strengths under the trade name Certican(R) for the prevention of organ rejection in heart and kidney transplant recipients. Certican was first approved in the EU in 2003.

In addition to renal cell carcinoma (RCC), RAD001 is being evaluated as a single agent or in combination with existing therapies in neuroendocrine tumors, lymphoma, breast, gastric, lung and other cancers, as well as tuberous sclerosis.

About renal cell carcinoma (RCC)

In the US, kidney cancer accounts for approximately 3% of all adult cancers. RCC, the most common type of kidney cancer, accounts for approximately 90% of malignant kidney tumors. In RCC, cancer cells develop in the lining of the kidney's tubes and grow into a tumor.

Disclaimer

The foregoing release contains forward-looking statements that can be identified by terminology such as "potential", "proposed", "believe", "should", "priority review", "potentially", "encouraged", "committed", "may", "suggest", or similar expressions, or by express or implied discussions regarding potential marketing approvals for RAD001 or regarding potential future revenues from RAD001. You should not place undue reliance on these statements. Such forward-looking statements reflect the current views of the Company regarding future events, and involve known and unknown risks, uncertainties and other fact
'/>"/>

SOURCE Novartis Pharmaceuticals Corporation
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6

Related medicine technology :

1. Cytels Clinical Innovation Experts Cyrus Mehta and Judith Quinlan Reveal Latest Adaptive Trial Successes at 44th Annual DIA Meeting
2. Latest Cell Publication Describes the Novel Kinase Regulators Using OriGenes Functional Kinome Collection
3. Baxter Presents Latest Clinical Trial Results of GAMMAGARD LIQUID Administered Subcutaneously
4. RAD001 Combined with Sandostatin LAR(R) Depot and as Monotherapy Controls Growth of Rare Pancreatic Neuroendocrine Tumors
5. RAD001 Granted Priority Review in the US Based on Potential to Fill Unmet Medical Need in Patients With Advanced Kidney Cancer
6. Early Data Presented at ASCO Show Potential of RAD001 to Enhance Efficacy of, and Overcome Resistance to, Breast Cancer Treatments
7. RAD001 More Than Doubles Time Without Tumor Growth After Failure of Standard Treatment in Patients With Advanced Kidney Cancer
8. Everolimus (RAD001) Significantly Extends Progression-Free Survival in Advanced Kidney Cancer Patients After Failure of Other Targeted Therapy
9. AstraZeneca and Targacept Announce Top-Line Results from Phase IIb Study of AZD3480 in Alzheimers Disease
10. Most Cancer Treatment Studies Arent Published, Study Finds
11. Enanta Initiates Phase 1 Study on EDP-322, an Oral Antibiotic With Activity Against Hospital- and Community-Acquired MRSA
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/24/2014)... 24, 2014 /PRNewswire-iReach/ -- Delivery of the Report ... placed. Photo - http://photos.prnewswire.com/prnh/20140723/129707 ... in-depth market survey on Global and Chinese Hemodialysis ... information of Hemodialysis Machine including its classification, application ... and China,s top manufacturers of Hemodialysis Machine listing ...
(Date:7/24/2014)... 2014 Questcor Pharmaceuticals, Inc. (NASDAQ: QCOR ... June 30, 2014. Three Months Ended 06/30/14Three Months Ended 06/30/13 ... Million , 51% Non-GAAP Net Sales , $278.8 Million ... $1.54 , $1.12 , 37% ... , 37%  Six Months Ended 06/30/14Six Months Ended ...
(Date:7/24/2014)... Scotland , July 24, 2014 Cancer patients ... gain access to state-of-the-art cancer treatment closer to home when ... next year. Varian Medical Systems (NYSE: VAR ... an order was placed in June for four TrueBeam™ medical ... systems, which offer fast and efficient radiotherapy and radiosurgery treatments, ...
Breaking Medicine Technology:Hemodialysis Machine Industry for Global and Chinese Markets Forecast to 2019 2Hemodialysis Machine Industry for Global and Chinese Markets Forecast to 2019 3Hemodialysis Machine Industry for Global and Chinese Markets Forecast to 2019 4Hemodialysis Machine Industry for Global and Chinese Markets Forecast to 2019 5Questcor Reports Record Second Quarter Financial Results 2Questcor Reports Record Second Quarter Financial Results 3Questcor Reports Record Second Quarter Financial Results 4Questcor Reports Record Second Quarter Financial Results 5Questcor Reports Record Second Quarter Financial Results 6Questcor Reports Record Second Quarter Financial Results 7Questcor Reports Record Second Quarter Financial Results 8Questcor Reports Record Second Quarter Financial Results 9Questcor Reports Record Second Quarter Financial Results 10Questcor Reports Record Second Quarter Financial Results 11Questcor Reports Record Second Quarter Financial Results 12Questcor Reports Record Second Quarter Financial Results 13Questcor Reports Record Second Quarter Financial Results 14Questcor Reports Record Second Quarter Financial Results 15Questcor Reports Record Second Quarter Financial Results 16Questcor Reports Record Second Quarter Financial Results 17Questcor Reports Record Second Quarter Financial Results 18Questcor Reports Record Second Quarter Financial Results 19Questcor Reports Record Second Quarter Financial Results 20Questcor Reports Record Second Quarter Financial Results 21Questcor Reports Record Second Quarter Financial Results 22Questcor Reports Record Second Quarter Financial Results 23Questcor Reports Record Second Quarter Financial Results 24Questcor Reports Record Second Quarter Financial Results 25Questcor Reports Record Second Quarter Financial Results 26Questcor Reports Record Second Quarter Financial Results 27Questcor Reports Record Second Quarter Financial Results 28Varian Medical Systems Selected to Equip First Satellite Radiotherapy Center in Scotland 2Varian Medical Systems Selected to Equip First Satellite Radiotherapy Center in Scotland 3
... Nov. 13 Warner Chilcott plc (Nasdaq: WCRX ... its ordinary shares by certain selling shareholders. The ... DLJ Merchant Banking, J.P. Morgan Partners (advised by CCMP ... institutional investors and members of the Company,s senior management. ...
... HAIKOU, China, Nov. 13 /PRNewswire-Asia-FirstCall/ -- Kun Run,Biotechnology, Inc. (the ... company in China that focuses on manufacturing and,sales of peptides ... quarter ended September 30, 2009. , , ... 65% from the third quarter of 2008 to a quarterly, ...
Cached Medicine Technology:Warner Chilcott Announces Secondary Equity Offering 2Warner Chilcott Announces Secondary Equity Offering 3Warner Chilcott Announces Secondary Equity Offering 4Kun Run Biotechnology, Inc. Announces Third Quarter 2009 Results 2Kun Run Biotechnology, Inc. Announces Third Quarter 2009 Results 3Kun Run Biotechnology, Inc. Announces Third Quarter 2009 Results 4Kun Run Biotechnology, Inc. Announces Third Quarter 2009 Results 5Kun Run Biotechnology, Inc. Announces Third Quarter 2009 Results 6Kun Run Biotechnology, Inc. Announces Third Quarter 2009 Results 7
(Date:7/25/2014)... Las Vegas, NV (PRWEB) July 25, 2014 ... hosting the one day Online Workshop ‘Consciousness is Power’ ... the globe are invited to attend this life transforming ... their consciousness to a higher level. Few days are ... During this workshop, Mahendra Trivedi and Trivedi Masters™ Dahryn ...
(Date:7/25/2014)... Fort Myers, FL (PRWEB) July 25, 2014 ... Apple iPhones, iPods, and iPads. The app provides a ... preventing painful and potentially dangerous sunburns and skin damage. ... about the sights, sounds, and capabilities of iTanSmart. ... by describing the app as a ‘better organized’ and ...
(Date:7/25/2014)... Silver®Care , for the first time in the United ... kill oral bacteria and airborne bacteria from the bathroom that ... the most common and important device in the prevention of ... to constant contamination by bacteria found in the mouth and ... mouth than anywhere else in the human body, and some ...
(Date:7/24/2014)... 2014 A few weeks have passed ... incredible high jump by Inika McPherson is a feat ... the USATF National Championships hosted the best track and ... McPherson, won US Nationals with the 2nd best jump ... for the biggest height over head jump in history. ...
(Date:7/24/2014)... Voted one of the most reliable online dress suppliers ... providing its new and old customers with the latest ... announced its new collection of high end wedding dresses. ... to the latest fashion trends. Additionally, they are now ... As a matter of fact, high end special occasion ...
Breaking Medicine News(10 mins):Health News:Mahendra Trivedi to Host an Online Workshop ‘Consciousness is Power’ 2Health News:Mahendra Trivedi to Host an Online Workshop ‘Consciousness is Power’ 3Health News:iTanSmart® Suntan App by UV Technologies, LLC Gets a ‘Big Thumbs Up’ from New York Times App Smart Columnist, Kit Eaton 2Health News:iTanSmart® Suntan App by UV Technologies, LLC Gets a ‘Big Thumbs Up’ from New York Times App Smart Columnist, Kit Eaton 3Health News:Silver®Care’s New Silver Antibacterial Toothbrushes Naturally Kill Oral Germs 2Health News:Silver®Care’s New Silver Antibacterial Toothbrushes Naturally Kill Oral Germs 3Health News:Setting A New High Jump World Record In Zensah® Compression 2Health News:Setting A New High Jump World Record In Zensah® Compression 3Health News:BellasDress Helps Brides Get High End Wedding Dresses for Their Romantic Weddings 2
... has succumbed to the accidental 17 overdoses of radiation, almost ... Norris, from Girvan in Ayrshire, was diagnosed with a brain ... Beatson Oncology Centre in Glasgow, Scotland's largest cancer hospital, which ... 20 years. ,Following a series of 17 radiotherapy sessions ...
... drug Velcade has been banned in England because the Government’s ... (NICE) has refused// to fund treatment, according to last night’s ... that Velcade should not be offered on the NHS to ... a course of Velcade has been estimated to cost between ...
... After all these years, mom was right. She knew broccoli ... this good.// ,“Everyone knows broccoli is good for you ... of some types of cancer. We want to know how ... says Janet V. Cross, Ph.D., Assistant Professor of Pathology at ...
... that they have found the brain’s natural antioxidant defense ... radicals//. ,According to the researchers at the ... from the harmful effects of toxic ‘free radicals’ that ... been associated with aging and certain degenerative brain diseases, ...
... novel look at the brains of adults with autism ... people with the developmental disorder may not communicate// with ... people. ,Researchers from the University of Washington’s Autism ... of the Society for Neuroscience on the first study ...
... break the hopes of a team of eminent plastic surgeons ... who are waiting for the// final approval from The Royal ... complete face transplant which would involve the complete replacement of ... is dead. ,Although the hospital had granted ...
Cached Medicine News:Health News:Cancer patient Dies of Massive Radiation Overdose 2Health News:Brain Regions Do Not Communicate Efficiently in Adults with Autism 2
The Atria 6100 delivers the highest level of clinical performance while incorporating cutting-edge technology to streamline clinic workflow. It offers timely, high-quality, and accurate ECG results c...
... The new Guidant VASOVIEW® HemoPro™ ... deliver a new level of ... for both the saphenous vein ... cut-and-seal capability, it lets you ...
Patient Monitor...
...
Medicine Products: